Literature DB >> 19956431

Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy.

Gaia Goteri, Serena Rupoli, Anna Campanati, Antonello Costagliola, Simona Sabato, Daniela Stramazzotti, Paola Picardi, Lucia Canafoglia, Stefano Pulini, Giulia Ganzetti, Anna Maria Offidani, Pietro Leoni.   

Abstract

Recruitment of neoplastic T cells to skin is a critical step in the pathogenesis of mycosis fungoides (MF) lesions. Cutaneous T-cell attracting chemokine (CTACK)/CCL27 attracts memory T cells to skin, resulting in increased cutaneous expression. The interactions between neoplastic cells and skin immune system require further elucidation. CTACK/CCL27 expression and density of dendritic cells (DC), CD8+ and CD4+ lymphocytes were investigated in skin lesions of 52 early-stage MF patients treated by interferon (IFN)-alpha in combination with photochemotherapy (psoralen plus ultraviolet A, PUVA). Skin lesion biopsies obtained at diagnosis and after treatment were studied by immunohistochemistry. Initial CTACK/CCL27 expression was abnormal/suprabasal in 36 patients. Normal/basal CTACK/CCL27 expression tended to correlate with a high DC density and low CD4+ cell density in the neoplastic infiltrate. Treatment induced a significant increase in CTACK/CCL27 expression (chi(2) test: P=0.004). Overall, 33 patients relapsed [median event-free survival (EFS), 46 months] during follow-up (median, 92.5 months, range, 43-165). Normal/basal CTACK/CCL27 expression at the end of treatment correlated with lower rates of recurrence and a longer median EFS (111 months vs. 39 months with suprabasal expression; log rank test: P=0.031). CTACK/CCL27 overexpression in early-stage MF might thus be related to a balance between neoplastic cells and immunomodulant DC. Normal CTACK/CCL27 expression after treatment designates a subset of patients with favorable disease behavior. The mechanisms underpinning CTACK/CCL27 overexpression after therapy in the remaining patients, who are at greater risk of recurrence, warrant further investigation.

Entities:  

Keywords:  CTACK/CCL27; Chemokine; dendritic cells; lymphocyte; mycosis fungoides

Year:  2009        PMID: 19956431      PMCID: PMC2776316     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  25 in total

1.  Increased CCR4 expression in cutaneous T cell lymphoma.

Authors:  Katalin Ferenczi; Robert C Fuhlbrigge; JackL Pinkus; Geraldine S Pinkus; Thomas S Kupper
Journal:  J Invest Dermatol       Date:  2002-12       Impact factor: 8.551

2.  CCL27-CCR10 interactions regulate T cell-mediated skin inflammation.

Authors:  Bernhard Homey; Harri Alenius; Anja Müller; Hortensia Soto; Edward P Bowman; Wei Yuan; Leslie McEvoy; Antti I Lauerma; Till Assmann; Erich Bünemann; Maili Lehto; Henrik Wolff; David Yen; Heather Marxhausen; Wayne To; Jonathon Sedgwick; Thomas Ruzicka; Percy Lehmann; Albert Zlotnik
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

3.  The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides.

Authors:  D Lu; M Duvic; L J Medeiros; R Luthra; D M Dorfman; D Jones
Journal:  Am J Clin Pathol       Date:  2001-03       Impact factor: 2.493

4.  CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells.

Authors:  J Morales; B Homey; A P Vicari; S Hudak; E Oldham; J Hedrick; R Orozco; N G Copeland; N A Jenkins; L M McEvoy; A Zlotnik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

5.  Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients.

Authors:  R van Doorn; C W Van Haselen; P C van Voorst Vader; M L Geerts; F Heule; M de Rie; P M Steijlen; S K Dekker; W A van Vloten; R Willemze
Journal:  Arch Dermatol       Date:  2000-04

Review 6.  Immunomodulators in the treatment of cutaneous lymphomas.

Authors:  Reinhard Dummer
Journal:  Expert Opin Biol Ther       Date:  2002-03       Impact factor: 4.388

7.  Increased serum cutaneous T cell-attracting chemokine (CCL27) levels in patients with atopic dermatitis and psoriasis vulgaris.

Authors:  Takashi Kakinuma; Hidehisa Saeki; Yuichiro Tsunemi; Hideki Fujita; Noriko Asano; Hiroshi Mitsui; Yayoi Tada; Motoshi Wakugawa; Takahiro Watanabe; Hideshi Torii; Mayumi Komine; Akihiko Asahina; Koichiro Nakamura; Kunihiko Tamaki
Journal:  J Allergy Clin Immunol       Date:  2003-03       Impact factor: 10.793

8.  Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.

Authors:  Y H Kim; S Chow; A Varghese; R T Hoppe
Journal:  Arch Dermatol       Date:  1999-01

9.  Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.

Authors:  Takashi Kakinuma; Makoto Sugaya; Koichiro Nakamura; Fumio Kaneko; Motoshi Wakugawa; Kouji Matsushima; Kunihiko Tamaki
Journal:  J Am Acad Dermatol       Date:  2003-01       Impact factor: 11.527

10.  Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides.

Authors:  Takatoshi Shimauchi; Kazunari Sugita; Daisuke Nishio; Hideka Isoda; Shoko Abe; Yoko Yamada; Ryosuke Hino; Makiko Ogata; Kenji Kabashima; Yoshiki Tokura
Journal:  J Dermatol Sci       Date:  2008-02-19       Impact factor: 4.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.